{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T17:15:43Z","timestamp":1789146943222,"version":"build-2803163510"},"reference-count":67,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":75,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Network meta-analysis (NMA) is a common approach to synthesizing efficacy and safety data from randomized controlled trials (RCTs). Within the last 5 years, there has been an increase in the number of published NMAs in the clinical literature. One potential risk of this trend is the acceptance of NMA findings with translation into therapeutic decisions for daily clinical practice without first critically assessing the validity of the method\u2019s core assumptions, including trial exchangeability and homogeneity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We use the recent surge in NMAs of advanced therapies for Crohn\u2019s disease (CD) and ulcerative colitis (UC) as a case study to illustrate the risks of overly permissive interpretation practices toward NMA methods and findings. We first highlight the potential violations of core NMA assumptions posed by known sources of heterogeneity across trials in CD and UC, and then outline several methodological strategies, ranging from data handling techniques to meta-regression, that can help to address or mitigate these violations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We put forward a checklist for users of NMAs to aid the interpretation of their results in the context of both methods and study inclusion\/exclusion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>While NMAs offer important insights into the relative treatment effects of different therapies and useful guidance to healthcare decision-makers, it is important that readers and users of NMA publications carefully review and critically evaluate the methods and results to ensure potential biases introduced by cross-trial heterogeneity are sufficiently mitigated and transparently documented, and that the results of any given NMA are interpreted within the context of the wider literature.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/crocol\/otag050","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T05:23:23Z","timestamp":1781501003000},"source":"Crossref","is-referenced-by-count":2,"title":["Considerations in reviewing network meta-analyses of heterogeneous clinical trial designs: a methodological review in Crohn\u2019s disease and ulcerative colitis"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4698-9948","authenticated-orcid":false,"given":"Christopher","family":"Ma","sequence":"first","affiliation":[{"name":"Division of Gastroenterology & Hepatology, Departments of Medicine and Community Health Sciences, University of Calgary , Calgary, Alberta,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric B","family":"Collins","sequence":"additional","affiliation":[{"name":"Medicus Economics LLC , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Tien","family":"Wang","sequence":"additional","affiliation":[{"name":"Medicus Economics LLC , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixi","family":"Teng","sequence":"additional","affiliation":[{"name":"Medicus Economics LLC , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren","family":"Stevens","sequence":"additional","affiliation":[{"name":"Medicus Economics LLC , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5247-940X","authenticated-orcid":false,"given":"Remo","family":"Panaccione","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Unit, Division of Gastroenterology and Hepatology, University of Calgary , Calgary, Alberta,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolly","family":"Sharma","sequence":"additional","affiliation":[{"name":"AbbVie Inc. , North Chicago, IL,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namita","family":"Joshi","sequence":"additional","affiliation":[{"name":"AbbVie Inc. , North Chicago, IL,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre A","family":"Morisset","sequence":"additional","affiliation":[{"name":"AbbVie Inc. , North Chicago, IL,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8556-8433","authenticated-orcid":false,"given":"Raja","family":"Atreya","sequence":"additional","affiliation":[{"name":"Department of Medicine 1, University Hospital Erlangen, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg , Erlangen,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2591-5165","authenticated-orcid":false,"given":"Gil Y","family":"Melmed","sequence":"additional","affiliation":[{"name":"F Widjaja Inflammatory Bowel Disease Institute, Cedars-Sinai , Los Angeles, CA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,13]]},"reference":[{"key":"2026091112565195400_otag050-B1","doi-asserted-by":"crossref","first-page":"101614","DOI":"10.1016\/j.bpg.2019.05.001","article-title":"Network meta-analysis to inform positioning of biologics in patients with Crohn\u2019s disease: promise and perils","volume":"38-39","author":"Singh","year":"2019","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"2026091112565195400_otag050-B2","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41575-020-0293-9","article-title":"Head-to-head trials in inflammatory bowel disease: past, present and future","volume":"17","author":"Pouillon","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2026091112565195400_otag050-B3","author":"Chaimani","year":"2024"},{"key":"2026091112565195400_otag050-B4","doi-asserted-by":"crossref","first-page":"S474","DOI":"10.1016\/j.jval.2024.10.2414","article-title":"MSR180 challenges in NMA methodology based on re-randomization vs treat-through trial designs","volume":"27","author":"Petersohn","year":"2024","journal-title":"Value in Health"},{"key":"2026091112565195400_otag050-B5","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/s41575-024-00989-y","article-title":"Interpreting modern randomized controlled trials of medical therapy in inflammatory bowel disease","volume":"21","author":"Ma","year":"2024","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2026091112565195400_otag050-B6","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"2026091112565195400_otag050-B7","author":"Dipen Patel"},{"key":"2026091112565195400_otag050-B8","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/ncprheum0732","article-title":"Primer: strengths and weaknesses of meta-analysis","volume":"4","author":"Finckh","year":"2008","journal-title":"Nat Clin Pract Rheumatol"},{"key":"2026091112565195400_otag050-B9","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2026091112565195400_otag050-B10","author":"Higgins","year":"2024"},{"key":"2026091112565195400_otag050-B11","doi-asserted-by":"crossref","first-page":"130","DOI":"10.7326\/0003-4819-159-2-201307160-00008","article-title":"Conceptual and technical challenges in network meta-analysis","volume":"159","author":"Cipriani","year":"2013","journal-title":"Ann Intern Med"},{"key":"2026091112565195400_otag050-B12","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jid.2018.10.028","article-title":"Research techniques made simple: network meta-analysis","volume":"139","author":"Watt","year":"2019","journal-title":"J Invest Dermatol"},{"key":"2026091112565195400_otag050-B13","doi-asserted-by":"crossref","DOI":"10.1002\/9781118951651","volume-title":"Network Meta-Analysis for Decision Making","author":"Dias","year":"2018"},{"key":"2026091112565195400_otag050-B14","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.cgh.2024.06.036","article-title":"The future of clinical trials in inflammatory bowel disease","volume":"23","author":"Ma","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026091112565195400_otag050-B15","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1097\/MIB.0000000000000909","article-title":"Interpreting registrational clinical trials of biological therapies in adults with inflammatory bowel diseases","volume":"22","author":"Ghosh","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"2026091112565195400_otag050-B16","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.cgh.2023.12.023","article-title":"Comparative efficacy of advanced therapies for achieving endoscopic outcomes in Crohn\u2019s disease: a systematic review and network meta-analysis","volume":"22","author":"Vuyyuru","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026091112565195400_otag050-B17","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S2468-1253(21)00312-5","article-title":"Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn\u2019s disease: a systematic review and network meta-analysis","volume":"6","author":"Singh","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026091112565195400_otag050-B18","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(21)00377-0","article-title":"Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis","volume":"7","author":"Lasa","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026091112565195400_otag050-B19","doi-asserted-by":"crossref","first-page":"otad009","DOI":"10.1093\/crocol\/otad009","article-title":"Efficacy and safety of advanced therapies for moderately to severely active ulcerative colitis at induction and maintenance: an indirect treatment comparison using Bayesian network meta-analysis","volume":"5","author":"Panaccione","year":"2023","journal-title":"Crohns Colitis 360"},{"key":"2026091112565195400_otag050-B20","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1093\/ecco-jcc\/jjab194","article-title":"Clinical, endoscopic, and safety placebo rates in induction and maintenance trials of Crohn\u2019s disease: meta-analysis of randomised controlled trials","volume":"16","author":"Almradi","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2026091112565195400_otag050-B21","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1093\/ecco-jcc\/jjab135","article-title":"Systematic review and meta-analysis: clinical, endoscopic, histological and safety placebo rates in induction and maintenance trials of ulcerative colitis","volume":"16","author":"Sedano","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2026091112565195400_otag050-B22","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet"},{"key":"2026091112565195400_otag050-B23","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"key":"2026091112565195400_otag050-B24","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1056\/NEJMoa2212728","article-title":"Upadacitinib induction and maintenance therapy for Crohn\u2019s disease","volume":"388","author":"Loftus","year":"2023","journal-title":"N Engl J Med"},{"key":"2026091112565195400_otag050-B25","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/jama.2024.12414","article-title":"Risankizumab for ulcerative colitis: two randomized clinical trials","volume":"332","author":"Louis","year":"2024","journal-title":"JAMA"},{"key":"2026091112565195400_otag050-B26","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"key":"2026091112565195400_otag050-B27","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(22)00466-4","article-title":"Risankizumab as maintenance therapy for moderately to severely active Crohn\u2019s disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial","volume":"399","author":"Ferrante","year":"2022","journal-title":"Lancet"},{"key":"2026091112565195400_otag050-B28","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med"},{"key":"2026091112565195400_otag050-B29","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1016\/j.cgh.2020.10.016","article-title":"Network meta-analysis of ulcerative colitis pharmacotherapies: carryover effects from induction and bias of the results","volume":"19","author":"Naessens","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026091112565195400_otag050-B30","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1186\/s12876-023-02938-6","article-title":"Network meta-analysis on efficacy and safety of different biologics for ulcerative colitis","volume":"23","author":"Chu","year":"2023","journal-title":"BMC Gastroenterol"},{"key":"2026091112565195400_otag050-B31","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1136\/gutjnl-2022-328052","article-title":"Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn\u2019s disease: systematic review and network meta-analysis","volume":"72","author":"Barberio","year":"2023","journal-title":"Gut"},{"key":"2026091112565195400_otag050-B32","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/S0140-6736(24)01762-8","article-title":"Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn\u2019s disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study","volume":"404","author":"Ferrante","year":"2024","journal-title":"Lancet"},{"key":"2026091112565195400_otag050-B33","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.dld.2023.06.009","article-title":"Maintenance of clinical remission with biologics and small molecules in inflammatory bowel disease according to trial design: meta-analysis","volume":"56","author":"Barberio","year":"2024","journal-title":"Dig Liver Dis"},{"key":"2026091112565195400_otag050-B34","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.14309\/ajg.0000000000003465","article-title":"ACG clinical guideline: management of Crohn\u2019s disease in adults","volume":"120","author":"Lichtenstein","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"2026091112565195400_otag050-B35","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.14309\/ajg.0000000000003463","article-title":"ACG clinical guideline update: ulcerative colitis in adults","volume":"120","author":"Rubin","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"2026091112565195400_otag050-B36","first-page":"S1","article-title":"What is first-line and what is second-line therapy in adult patients with moderate to severe Crohn\u2019s disease?","volume":"8(Suppl 2)","author":"Panaccione","year":"2025","journal-title":"J Can Assoc Gastroenterol"},{"key":"2026091112565195400_otag050-B37","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0140-6736(24)01927-5","article-title":"Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies","volume":"405","author":"Rubin","year":"2025","journal-title":"Lancet"},{"key":"2026091112565195400_otag050-B38","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3389\/fmed.2020.00517","article-title":"Personalizing treatment in IBD: hype or reality in 2020? can we predict response to anti-TNF?","volume":"7","author":"Atreya","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"2026091112565195400_otag050-B39","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/apt.14550","article-title":"Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease","volume":"47","author":"Barr\u00e9","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2026091112565195400_otag050-B40","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/1741-7015-12-93","article-title":"A process for assessing the feasibility of a network meta-analysis: a case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancer","volume":"12","author":"Cope","year":"2014","journal-title":"BMC Med"},{"key":"2026091112565195400_otag050-B41","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.cgh.2020.01.008","article-title":"First- and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: an updated network meta-analysis","volume":"18","author":"Singh","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026091112565195400_otag050-B42","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/apt.70295","article-title":"Network meta-analysis: comparative efficacy of biologics and small molecules in the induction and maintenance of remission in Crohn\u2019s disease","volume":"62","author":"Shehab","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"key":"2026091112565195400_otag050-B43","year":"2020"},{"key":"2026091112565195400_otag050-B44","year":"2018"},{"key":"2026091112565195400_otag050-B45","first-page":"29","article-title":"Incorporating alternative design clinical trials in network meta-analyses","volume":"7","author":"Thorlund","year":"2015","journal-title":"Clin Epidemiol"},{"key":"2026091112565195400_otag050-B46","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1586\/17474124.2015.1024657","article-title":"Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designs","volume":"9","author":"Thorlund","year":"2015","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"2026091112565195400_otag050-B47","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1080\/03007995.2020.1716701","article-title":"Efficacy of ustekinumab vs. advanced therapies for the treatment of moderately to severely active ulcerative colitis: a systematic review and network meta-analysis","volume":"36","author":"Welty","year":"2020","journal-title":"Curr Med Res Opin"},{"key":"2026091112565195400_otag050-B48","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1007\/s12325-025-03183-x","article-title":"One-year efficacy of guselkumab versus advanced therapies for the treatment of moderately to severely active Crohn\u2019s disease: a network meta-analysis","volume":"42","author":"Disher","year":"2025","journal-title":"Adv Ther"},{"key":"2026091112565195400_otag050-B49","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1016\/j.cgh.2020.11.036","article-title":"Reply","volume":"19","author":"Singh","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026091112565195400_otag050-B50","year":"2023"},{"key":"2026091112565195400_otag050-B51","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1080\/03007995.2019.1580094","article-title":"Treatment sequence network meta-analysis in Crohn\u2019s disease: a methodological case study","volume":"35","author":"Varu","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"2026091112565195400_otag050-B52","year":"2017"},{"key":"2026091112565195400_otag050-B53","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1038\/s41433-022-01943-5","article-title":"A clinician\u2019s guide to network meta-analysis","volume":"36","author":"Phillips","year":"2022","journal-title":"Eye (Lond)"},{"key":"2026091112565195400_otag050-B54","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s12887-018-1132-9","article-title":"Network meta-analysis: users\u2019 guide for pediatricians","volume":"18","author":"Al Khalifah","year":"2018","journal-title":"BMC Pediatr"},{"key":"2026091112565195400_otag050-B55","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.cgh.2025.01.012","article-title":"Real-world effectiveness and safety of upadacitinib in Crohn\u2019s disease: a multicenter study","volume":"23","author":"Devi","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026091112565195400_otag050-B56","doi-asserted-by":"crossref","first-page":"317","DOI":"10.14309\/ajg.0000000000002047","article-title":"The real-world effectiveness and safety of ustekinumab in the treatment of Crohn\u2019s disease: results from the SUCCESS consortium","volume":"118","author":"Johnson","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"2026091112565195400_otag050-B57","doi-asserted-by":"crossref","first-page":"i1586","DOI":"10.1093\/ecco-jcc\/jjae190.1006","article-title":"P0832 real-world effectiveness of risankizumab in Crohn\u2019s disease: the UK experience","volume":"19(Suppl_1)","author":"Elford","year":"2025","journal-title":"J Crohn\u2019s Colit"},{"key":"2026091112565195400_otag050-B58","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1093\/ibd\/izz204","article-title":"Real-world effectiveness of advanced therapies among patients with moderate to severe ulcerative colitis in the United States","volume":"26","author":"Long","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"2026091112565195400_otag050-B59","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.cgh.2024.06.050","article-title":"Modern advanced therapies for inflammatory bowel diseases: practical considerations and positioning","volume":"23","author":"Fudman","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026091112565195400_otag050-B60","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"2026091112565195400_otag050-B61","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12874-025-02499-0","article-title":"Ranking of treatments in network meta-analysis: incorporating minimally important differences","volume":"25","author":"Curteis","year":"2025","journal-title":"BMC Med Res Methodol"},{"key":"2026091112565195400_otag050-B62","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13643-017-0473-z","article-title":"Approaches to interpreting and choosing the best treatments in network meta-analyses","volume":"6","author":"Mbuagbaw","year":"2017","journal-title":"Syst Rev"},{"key":"2026091112565195400_otag050-B63","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1093\/aje\/kwab278","article-title":"Introducing the treatment hierarchy question in network meta-analysis","volume":"191","author":"Salanti","year":"2022","journal-title":"Am J Epidemiol"},{"key":"2026091112565195400_otag050-B64","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jclinepi.2023.02.016","article-title":"A multifaceted graphical display, including treatment ranking, was developed to aid interpretation of network meta-analysis","volume":"157","author":"Nevill","year":"2023","journal-title":"J Clin Epidemiol"},{"key":"2026091112565195400_otag050-B65","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","article-title":"Ranking treatments in frequentist network meta-analysis works without resampling methods","volume":"15","author":"Rucker","year":"2015","journal-title":"BMC Med Res Methodol"},{"key":"2026091112565195400_otag050-B66","doi-asserted-by":"crossref","first-page":"m3907","DOI":"10.1136\/bmj.m3907","article-title":"GRADE approach to drawing conclusions from a network meta-analysis using a partially contextualised framework","volume":"371","author":"Brignardello-Petersen","year":"2020","journal-title":"BMJ"},{"key":"2026091112565195400_otag050-B67","doi-asserted-by":"crossref","first-page":"e1003082","DOI":"10.1371\/journal.pmed.1003082","article-title":"CINeMA: an approach for assessing confidence in the results of a network meta-analysis","volume":"17","author":"Nikolakopoulou","year":"2020","journal-title":"PLoS Med"}],"container-title":["Crohn\u2019s &amp; Colitis 360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/advance-article-pdf\/doi\/10.1093\/crocol\/otag050\/68524520\/otag050.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/8\/2\/otag050\/68524520\/otag050.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/8\/2\/otag050\/68524520\/otag050.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:57:04Z","timestamp":1789145824000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article\/doi\/10.1093\/crocol\/otag050\/8707844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":67,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4,22]]}},"URL":"https:\/\/doi.org\/10.1093\/crocol\/otag050","relation":{},"ISSN":["2631-827X"],"issn-type":[{"value":"2631-827X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2026,4]]},"article-number":"otag050"}}